Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting [Yahoo! Finance]
Kronos Bio, Inc. (KRON)
Company Research
Source: Yahoo! Finance
lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California. “We are excited to present our data at AACR showing that targeting p300's enzymatic KAT domain can selectively downregulate IRF4, a long sought after transcription factor dependency in multiple myeloma. Although p300 is an essential gene, our data show that through its relationship as a critical IRF4 cofactor, we can achieve selective antiproliferative effects against myeloma cells,” said Charles Lin, Ph.D., Senior Vice President, Research and Development of Kronos Bio. Details for the AACR 2024 abstracts are as follows: Title: p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma Presenter: Charles Y. Lin, Ph.D., Kronos Bio Abstract #: Poster Session: Chromatin Organization and Regulators of Chromatin B
Show less
Read more
Impact Snapshot
Event Time:
KRON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRON alerts
High impacting Kronos Bio, Inc. news events
Weekly update
A roundup of the hottest topics
KRON
News
- Kronos Bio, Inc. (NASDAQ: KRON) had its price target lowered by analysts at HC Wainwright from $2.50 to $2.25. They now have a "buy" rating on the stock.MarketBeat
- Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]Yahoo! Finance
- Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
KRON
Earnings
- 3/21/24 - Beat
KRON
Sec Filings
- 4/29/24 - Form ARS
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form DEF
- KRON's page on the SEC website